In a report published on May 10, Camilo Lyon of BTIG a to buy Rating on Trulieve Cannabis (TCNNF) with a target price of C $ 102.00. The company’s shares closed at $ 38.97 last Friday.
According to TipRanks.com, Lyon currently ranks 0 stars on a 0 to 5 star ranking with an average return of -4.2% and a success rate of 41.8%. Lyon covers the consumer goods sector and focuses on stocks like Canada Goose Holdings, Lululemon Athletica and The Lovesac Company.
The word on the street in general suggests a consensus rating from Strong Buy analysts for Trulieve Cannabis with an average price target of $ 70.32, up 77.7% from current levels. In a report published on April 28, Needham also assigned the stock a buy rating with a price target.
See Analysts Recommended Stocks Today >>
Based on Trulieve Cannabis’ latest earnings release for the quarter ended December 31, the company had quarterly sales of $ 168 million and net income of $ 37.7 million. By comparison, the company had revenue of $ 79.69 million and a GAAP net loss of $ 79.41 million for the past year.
Based on recent insider activity from 21 insiders, the stock’s insider sentiment is positive for the stock. This means that more insiders bought their TCNNF shares in the last quarter than they did earlier this year.
TipRanks has tracked 36,000 company insiders and found that some of them are better than others when it comes to the timing of their transactions. See which 3 stocks are most likely to move after their inside activity.
Trulieve Cannabis Corp. offers medicinal cannabis products. The company cultivates and manufactures its products in-house and sells them via home delivery to its branded stores and directly to patients. Products include smokable flowers, inhalation, oral, sublingual, topical, internasal, and concentrates. The company was founded on September 21, 2018 and is headquartered in Quincy, FL.
Read more about TCNNF: